The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I); in which A, R1, R2, R3, R4, R5 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. [structure]

Claims

9 · 1 independent · depth 2

9 granted claims

›1.independentA compound of general formula (I):+8

›2.↳ 1The compound according to claim 1, wherein:d2

›3.↳ 1The compound according to claim 1, wherein:d2

›4.↳ 1The compound according to claim 1, wherein:d2

›5.↳ 1The compound according to claim 1, wherein:d2

›6.↳ 1The compound according to claim 1, which is selected from the group consisting of:n3-(4-Methoxyfuro[3,2-c]pyridin-2-yl)-6-[(2R)-morpholin-2-ylmethoxy]…d2

›7.↳ 1A method of preparing a compound according to claim 1, said method comprising reacting an intermediate compound of general formula (V):d2

›8.↳ 1A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable diluent or carrier.d2

›9.↳ 1A pharmaceutical combination comprising:none or more first active ingredients selected from compounds according to claim 1, andone or more second acti…d2

Classifications

5 codes

IPC · International Patent Classification

Section A — Human necessities

A61K45/06
A61K31/5025
A61K31/5377

Section C — Chemistry; metallurgy

C07D405/04
C07D487/04

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

3.0 y

1,091 days filing → grant

Office actions

after a restriction

Responses

1 RCE

Examiner

Wu-Cheng Winston Shen

art unit 1628 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 31 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

1 priority documents

›Priority documents — 1

Type	Document	Date
related publication	US 20150094300 A1	2 Apr 2015

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.